Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

Go back to Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
(NASDAQ: EWTX) Delayed: 36.81 +1.99 (5.72%)
Previous Close $34.82    52 Week High
Open $35.78    52 Week Low
Day High $37.14    P/E N/A 
Day Low $35.39    EPS
Volume 2,007,584